Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

Wenbin Qian, Yun Liang

Blood (2025) 146 (Supplement 1): 7215.

https://doi.org/10.1182/blood-2025-7215

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Lixia Sheng, Wen Lei, Duo Wu, Yi Zhang, Yanli Lai, Shuyan Wang, Duobing Zou, Ping Zhang, Kaihong Xu, Shanhao Tang, Huijie Hu, Tongyu Li, Qitian Mu, Xiaofei Ye, Hui Liu, Wenbin Qian, Guifang Ouyang

Blood (2025) 146 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2025-1929

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Wenbin Qian, Xuzhao Zhang, Yang Xu, Yun Liang

Blood (2025) 146 (Supplement 1): 5722.

https://doi.org/10.1182/blood-2025-5722

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2025-3684

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Trial in progress: Romiplostim N01 combined with immunosuppressive therapy in patients diagnosed with non-severe aplastic anemia, a Phase II study

Yun Zhang, Bo Wang, Dijiong Wu, Shu Deng, Jianping Shen, Qinghong Yu, Wenbin Liu, Tonglin Hu, Wenbin Qian, Dan Chen, Weiying Feng, Baodong Ye

Blood (2025) 146 (Supplement 1): 6735.

https://doi.org/10.1182/blood-2025-6735

Published: 2025

Journal Articles

Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma

Xianggui Yuan, Yurong Huang, Qunyi Guo, Yaping Xie, Nengwen Xu, Xueli Jin, Jiefeng Tong, Yun Liang, Wenbin Qian

Blood (2025) 146 (Supplement 1): 5461.

https://doi.org/10.1182/blood-2025-5461

Published: 2025

Journal Articles

Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large B-cell lymphoma with high-risk CNS-IPI

Xibin Xiao, Wenbin Qian, Lixia Sheng, Jun Wang, Huyi Lei, Xian Li, Jing Xie, Changqian Bao, Huawei Jiang

Blood (2025) 146 (Supplement 1): 5460.

https://doi.org/10.1182/blood-2025-5460

Published: 2025

Journal Articles

FOXO1⁺themis⁺ memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma

Wenbin Qian, Aiqi Zhao, Hui Liu, Wen Lei, Minghuan Zhang, Tianshu Yu, Shuhan Zhong

Blood (2025) 146 (Supplement 1): 3707.

https://doi.org/10.1182/blood-2025-3707

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

Xianggui Yuan, Qian Luo, Yurong Huang, Chaoyi Li, Teng Yu, Shanshan Guo, Qunyi Guo, Xueli Jin, Jiefeng Tong, Aiqi Zhao, Wen Lei, Xian Li, Baizhou Li, Shumei Wei, Wenbin Qian, Yun Liang

Blood (2025) 146 (Supplement 1): 5304.

https://doi.org/10.1182/blood-2025-5304

Published: 2025

Journal Articles

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

Wenbin Qian, Panpan Chen, Hui Liu, Wen Lei

Blood (2025) 146 (Supplement 1): 7687.

https://doi.org/10.1182/blood-2025-7687

Published: 2025

Journal Articles

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Jiefeng Tong, Songfu Jiang, Qian Luo, Shanhu Qian, Guifang Ouyang, Yanli Lai, Huifang Jiang, Yuxia Jiang, Hui Zeng, Baodong Ye, Wei Jiang, Wenbin Qian

Blood (2024) 144 (Supplement 1): 7762.

https://doi.org/10.1182/blood-2024-204522

Published: 2024

Journal Articles

Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Wenbin Qian, Hui Liu, Wen Lei, Linqin Wang, Panpan Chen

Blood (2024) 144 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2024-205376

Published: 2024

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Wenbin Qian, Wen Lei, Hui Liu, Wei Chen, Yun Liang, Yi Eve Sun, Xiangmin Tong, Aibin Liang

Blood (2024) 144 (Supplement 1): 7209.

https://doi.org/10.1182/blood-2024-202988

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Trial in progress: Romiplostim N01 combined with immunosuppressive therapy in patients diagnosed with non-severe aplastic anemia, a Phase II study

Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma

Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large B-cell lymphoma with high-risk CNS-IPI

FOXO1⁺themis⁺ memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment

Real-World Study of Glofitamab for the Treatment of Relapse or Refractory Diffuse Large B-Cell Lymphoma in East China

Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Safety and Feasibility of a 41BB Co-Stimulated CD19 CAR-NK Cell Therapy in Refractory/Relapsed Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only